Patent application number | Description | Published |
20090118316 | Methods for Augmenting Bone - The present invention relates to methods of stimulating osteoblast function with a PYK2 inhibitor in subjects with osteoporosis, bone fractures, non-unions, pseudoarthroses, periodontal disease or other disorders of bone metabolism. Optionally, the method further comprises administration of a second therapeutic bone agent. The present invention also relates to methods to identify a PYK2 inhibitor effective as a therapeutic bone agent comprising administering a test agent to an osteoblast-like cell and determining if osteoblast function is stimulated. Optionally, the identifying method further comprises contacting the test agent with PYK2 and determining if PYK2 activity is inhibited. | 05-07-2009 |
20110044978 | METHOD FOR TREATING BONE FRACTURE - The invention provides a method of enhancing bone fracture healing involving administering a sclerostin inhibitor. In one aspect, the invention includes use of a therapeutically effective amount of sclerostin binding agent to treat a bone fracture, wherein one or more administrations of the sclerostin binding agent are administered over a treatment period lasting at least two weeks and beginning within two weeks of the fracture. | 02-24-2011 |
20130209475 | DKK1 ANTIBODIES AND METHODS OF USE - The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed. | 08-15-2013 |
20140271654 | METHODS FOR TREATING BONE GAP DEFECTS - The invention provides a method of enhancing bone gap defect healing involving administering a sclerostin inhibitor. | 09-18-2014 |
20140314776 | METHOD OF TREATING ALVEOLAR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES - The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof. | 10-23-2014 |
Patent application number | Description | Published |
20120112703 | System and Method for Managing a Battery - A method for managing a battery with multiple battery cells is disclosed. The method includes monitoring parameters of the battery cells by an information acquisition unit. Parameters of the battery cells include individual cell voltages. The method further includes selecting, by a controller one of multiple charging modes in which the battery cells are charged according to the cell voltages. The charging modes include a constant current charging mode, a constant voltage charging mode, and a pulse charging mode. | 05-10-2012 |
20120319657 | BATTERY MANAGEMENT SYSTEM - A battery system and method is disclosed The battery system includes a plurality of battery modules configured to receive a current from a power supply and further configured to store and provide electrical energy from the power supply to a load. Each of the plurality of battery modules includes at least one battery and battery management circuitry (BMC) configured to monitor and detect data received from the at least one battery. The battery system further includes central control circuitry (CCC) configured to receive the data from each BMC. The control circuitry is configured to balance each of the plurality of the battery modules, wherein the control circuitry is configured to independently charge or discharge the at least one battery of each of the plurality of battery modules based on the data received from the BMC of each of the plurality of battery modules. | 12-20-2012 |
20130099726 | System and Method for Charging of Battery - A battery charging system for charging a battery with a plurality of battery cells. The battery charging system includes a battery charger and a battery management unit. The battery management unit includes a plurality of balancing circuits for controlling charging of each battery cell. The battery charging system can charge the battery in different stages depending on the voltage of each battery cell. | 04-25-2013 |
20130200850 | Circuit and Method for Cell Balancing - A balancing circuit for balancing multiple cells in a battery. The cell balancing circuit includes a first shunt path connected in parallel to a first cell, a controller coupled to the first shunt path, a timer and a storage unit. The controller balances the cells and detects balance conditions of each cell. The timer measures pre-balance times and balance times for each cell. The storage unit stores the pre-balance times and balance times. The controller pre-balances the first cell by enabling the first shunt path for a first pre-balance time and balances the first cell by enabling the first shunt path for a first balance time if an unbalance condition of the first cell is detected by the controller, and updates the first pre-balance time for each balancing cycle based on the first pre-balance time and the first balance time from a previous balancing cycle. | 08-08-2013 |
20150188336 | Circuit and Method for Cell Balancing - A balancing circuit for balancing multiple cells in a battery. The cell balancing circuit includes a first shunt path connected in parallel to a first cell, a controller coupled to the first shunt path, a timer and a storage unit. The controller balances the cells and detects balance conditions of each cell. The timer measures pre-balance times and balance times for each cell. The storage unit stores the pre-balance times and balance times. The controller pre-balances the first cell by enabling the first shunt path for a first pre-balance time and balances the first cell by enabling the first shunt path for a first balance time if an unbalance condition of the first cell is detected by the controller, and updates the first pre-balance time for each balancing cycle based on the first pre-balance time and the first balance time from a previous balancing cycle. | 07-02-2015 |
Patent application number | Description | Published |
20090133136 | Inducible SIRNA expression cassette and method of use - An inducible siRNA expression polynucleotide and methods for its use are provided. The expression polynucleotide comprises a bicistronic expression cassette that encodes a repressor and a detectable marker, wherein the repressor controls expression of siRNA expression in the absence of an inducer. | 05-21-2009 |
20090305904 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2. BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 12-10-2009 |
20110190168 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is Closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is Widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 08-04-2011 |
20120322050 | USING IMPEDANCE-BASED CELL RESPONSE PROFILING TO IDENTIFY PUTATIVE INHIBITORS FOR ONCOGENE ADDICTED TARGETS OR PATHWAYS - Use of impedance devices in methods of generating a time dependent cellular profiles (TCRP) for the modulation of oncogene addicted cells and comparing the impedance-based TCRP to controls or knowns to identify signature time dependent cellular profiles. | 12-20-2012 |
20130143254 | CO-CULTURE DEVICE ASSEMBLY - An insert device and co-culture device assembly incorporating the insert device, which includes an insert chamber with two fluid impermeable side walls that extend from a microporous bottom to an open top to form an inner cavity. The first side wall is shaped to form a convex arc that follows between about half of a circumference of the well and less than an entire circumference of the well. The second side wall joins ends of the first side wall and protrudes inward towards a center of the convex arc. A flange extends outward from or beneath the top and is notched to form a gap adjacent to the second side wall, which forms an access port allowing access to the lower chamber with a micropipette tip when the insert device is inserted into a well of a single or multi-well plate. | 06-06-2013 |
Patent application number | Description | Published |
20080209540 | FIREWALL INCLUDING LOCAL BUS - A gateway for screening packets transferred over a network. The gateway includes a plurality of network interfaces, a memory and a memory controller. Each network interface receives and forwards messages from a network through the gateway. The memory temporarily stores packets received from a network. The memory controller couples each of the network interfaces and is configured to coordinate the transfer of received packets to and from the memory using a memory bus. The gateway includes a firewall engine coupled to the memory bus. The firewall engine is operable to retrieve packets from the memory and screen each packet prior to forwarding a given packet through the gateway and out an appropriate network interface. A local bus is coupled between the firewall engine and the memory providing a second path for retrieving packets from memory when the memory bus is busy. | 08-28-2008 |
20100180026 | RECYCLING ITEMS IN A NETWORK DEVICE - A network device includes a data structure and an ager. The data structure includes a group of positions. One or more of the positions are associated with at least one item. The ager is configured to sequentially analyze each position of the group of positions, and recycle, at each analyzed position, any item associated with the analyzed position. | 07-15-2010 |
20100281532 | FIREWALL INCLUDING LOCAL BUS - A gateway for screening packets transferred over a network. The gateway includes a plurality of network interfaces, a memory and a memory controller. Each network interface receives and forwards messages from a network through the gateway. The memory temporarily stores packets received from a network. The memory controller couples each of the network interfaces and is configured to coordinate the transfer of received packets to and from the memory using a memory bus. The gateway includes a firewall engine couples to the memory bus. The firewall engine is operable to retrieve packets from the memory and screen each packet prior to forwarding a given packet through the gateway and out an appropriate network interface. A local bus is coupled between the firewall engine and the memory providing a second path for retrieving packets from memory when the memory bus is busy. | 11-04-2010 |
20110310742 | GUARANTEED BANDWIDTH SHARING IN A TRAFFIC SHAPING SYSTEM - In one aspect the invention provides a method for allocating bandwidth in a network appliance where the network appliance includes a plurality of guaranteed bandwidth buckets used to evaluate when to pass traffic through the network appliance. The method includes providing a shared bandwidth bucket associated with a plurality of the guaranteed bandwidth buckets, allocating bandwidth to the shared bandwidth bucket based on the underutilization of bandwidth in the plurality of guaranteed bandwidth buckets and sharing excess bandwidth developed from the underutilization of the guaranteed bandwidth allocated to the individual guaranteed bandwidth buckets. The step of sharing includes borrowing bandwidth from the shared bandwidth bucket by a respective guaranteed bandwidth bucket to allow traffic to pass immediately through the network appliance. | 12-22-2011 |
20140215598 | NETWORK SECURITY DEVICE - Methods and apparatus, including computer program products, implementing and using techniques for processing a data packet. An input port receives a data packet, a switching board classifies the data packet, determines whether the data packet should be accepted, and switches the data packet to a management board if the data packet is a first data packet in a session, and to a processing board if the data packet is not a first data packet in a session. A management board receives a data packet from the switching board, examines the data packet and forwards the data packet to one of the processing boards. One or more processing boards receives non-first data packets from the switching board and data packets from the management board and processes the data packets. A firewall and a secure gateway with firewall and virtual private network functionality for processing a data packet are also described. | 07-31-2014 |
Patent application number | Description | Published |
20090142807 | FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 06-04-2009 |
20090246190 | ANTI-VEGF ANTIBODY - An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. | 10-01-2009 |
20090269357 | ANTI-TNFalpha ANTIBODY - An antibody that binds TNF α and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2. | 10-29-2009 |
20100204059 | CDR-Anchored Amplification Method - A method of obtaining nucleic acid encoding a plurality of antibodies is provided. In certain embodiments, the method comprises obtaining from an immunized animal nucleic acid encoding the amino acid sequence of the heavy and light chains of a second antibody that binds to the antigen as a first antibody and differs in amino acid sequence to the first antibody, wherein the obtaining is done by amplification using: i. a first primer pair that includes oligonucleotides are complementary to CDR-encoding regions first antibody. | 08-12-2010 |
20110008367 | ANTI-VEGF ANTIBODY - An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. | 01-13-2011 |
20110020934 | Fusion Partner for Production of Monoclonal Rabbit Antibodies - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 01-27-2011 |
20120225060 | ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE - The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases. | 09-06-2012 |
20120238013 | FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 09-20-2012 |
20130017555 | FACS-BASED METHOD FOR OBTAINING AN ANTIBODY SEQUENCE - In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen. | 01-17-2013 |
20130330355 | ANTI-IL-1BETA ANTIBODIES AND METHODS OF USE - The present invention provides anti-IL-1β monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases. | 12-12-2013 |
20140004566 | Fusion Partner for Production of Monoclonal Rabbit Antibodies | 01-02-2014 |
20140322239 | ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE - The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases. | 10-30-2014 |
20140349393 | Fusion Partner for Production of Monoclonal Rabbit Antibodies - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 11-27-2014 |
20140377282 | ANTI-KDR ANTIBODIES AND METHODS OF USE - The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity. | 12-25-2014 |